Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention
Information source: Sheba Medical Center
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Edema; Cerebral Edema
Intervention: Tadalafil and acetazolamide (Drug); Acetazolamide (Drug)
Sponsored by: Sheba Medical Center
To evaluate the additive value of tadalafil given together with Diamox (acetazolamide) in
preventing acute mountain sickness in travelers to high altitude areas.
Official title: Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: Results will be evaluated by using the Lake Louise AMS scoring system
A randomized controlled study comparing:
Tadalafil [20mg x1/day] and acetazolamide [125mg x2 day], versus Acetazolamide [125mg x2
day] alone, in trekkers to altitude > 3,000 m.
Minimum age: 18 Years.
Maximum age: N/A.
- Participant in trekking to high altitude
- Agreement to sign the informed consent.
- No agreement to sign informed consent.
Locations and Contacts
Center of Geographic Medicine, Tel Hashomer, Israel; Recruiting
eli Schwartz, MD, Phone: 03-5302422, Email: email@example.com
Eli Schwartz, MD, Principal Investigator
Eyal Leshem, MD, Sub-Investigator
Sheba Medical Ctr., Tel Hashomer, Israel; Recruiting
Eli Schwartz, MD, Phone: 03-5302168, Email: firstname.lastname@example.org
Eyal lershem, MD, Phone: 03-5303500, Email: email@example.com
Tel Hashomer, Israel; Recruiting
Eli Schwartz, MD, Phone: 03-5302168
Eyal Leshem, MD, Phone: 03-5303500
Schwartz Eli, MD, Principal Investigator
Eyal leshem, MD, Sub-Investigator
Starting date: January 2006
Last updated: February 1, 2010